MedTrace Logo

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

NCT07251595 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2026-02-18

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.

Conditions

  • Non-segmental Vitiligo

Interventions

DRUG

SHR0302 Tablets

SHR0302 tablets.

DRUG

SHR0302 Base Gel

SHR0302 Base gel.

DRUG

SHR0302 Placebo Tablets

SHR0302 placebo tablets.

DRUG

SHR0302 Base Placebo Gel

SHR0302 Base placebo gel.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-05
Primary Completion
2027-03-31
Completion
2027-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07251595 on ClinicalTrials.gov